American Association for Cancer Research

Synthetic Lethal Approaches to Cancer Vulnerabilities

Synthetic Lethal Approaches to Cancer VulnerabilitiesAACR Precision Medicine Series:
Synthetic Lethal Approaches to Cancer Vulnerabilities
May 17-20, 2013
Hyatt Regency Bellevue
Bellevue, WA

William C. Hahn, Dana-Farber Cancer Institute, Boston, MA
Sebastian Nijman, Research Center for Molecular Medicine – CeMM, Vienna, Austria
Louis M. Staudt, National Cancer Institute, Bethesda, MD


The focus of this AACR Precision Medicine Series conference was to bring together basic, translational, and clinical scientists working on targeting codependencies and other context-specific dependencies. The concept of synthetic lethality is derived from classical genetics and has been widely explored in model organisms. Recent advances in technology now permit similar types of studies to be performed in mammalian cells, and the demonstration that PARP inhibitors show clinical responses in breast and ovarian cancer patients that harbor BRCA1 mutations provides proof-of-principle evidence that targeting such codependencies represents a promising therapeutic strategy.

* Adobe Acrobat Reader required

Please visit the AACR Meetings & Workshops Calendar for a complete list of upcoming programs.